Jan 12, 2022 / 02:45PM GMT
Ruizhi Qin - JPMorgan Chase & Co, Research Division - Analyst
All right. Good morning, everyone. Welcome to day 3 of the JPMorgan Healthcare Conference. This is Julia Qin from the life science team at JPMorgan, and it's my great pleasure to introduce you to our next company presentation by Repligen. Just as a reminder, if you have a question, you can submit it through the website.
And with that, let me turn it over to Tony.
Anthony J. Hunt - Repligen Corporation - CEO, President & Director
Great. Thanks, Julia. It's my pleasure to be here. here at JPMorgan in 2022 and really talk a little bit about all the advances that have happened at Repligen in the world to bioprocessing over the last 12 months. I think the presentation today, my goal is to really walk everybody through the evolution of the company, especially as we've migrated through the world of COVID vaccines and cell and gene therapy. Also I want to really talk about the expansion of our strategy as we create new verticals for the company, and then set the stage for the next 5 years. We
Repligen Corp at JPMorgan Healthcare Conference (Virtual) Transcript
Feb 08, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers